HCPCS Level II code C1721 denotes an implantable dual-chamber cardioverter-defibrillator device used for cardiac rhythm management and delivery of defibrillation and pacing therapies. These devices are critical in preventing sudden cardiac death for patients with high-risk ventricular arrhythmias and for selected patients requiring both atrial and ventricular pacing capabilities. Nationally, implantable cardioverter-defibrillators (ICDs) represent a significant component of advanced cardiac care and capital medical device spending.

This analysis covers coverage and billing considerations for major payers including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find benchmarks on payer coverage patterns, common billing modifiers, and clinical context for device use. The content summarizes typical sites of service for implantation and follow-up, highlights where policy updates may affect coding and reimbursement, and outlines the clinical scenarios that commonly justify device implantation.

The publication is intended for revenue cycle leaders, cardiology program directors, and billing professionals seeking a concise reference to HCPCS Level II code C1721, its clinical role, and payer landscape. Data not available in the input is noted where applicable elsewhere in the full publication.